Biogen Pharmachem adopts FY26 financials, reappoints Bunkar at AGM
- Biogen Pharmachem Industries adopted audited financial statements for FY26 at its 31st AGM
- Kelash Bunkar was reappointed as a director retiring by rotation
- M/s. Goenka Mehta & Associates appointed as statutory auditors for the company

*this image is generated using AI for illustrative purposes only.
Biogen Pharmachem Industries Limited adopted its audited financial statements for the fiscal year ended March 31, 2026, during its 31st Annual General Meeting held on September 29, 2026. The meeting also saw the reappointment of Kelash Bunkar as a director and the appointment of new statutory auditors.
The Annual General Meeting was conducted via Video Conferencing and Other Audio Visual Means, commencing at 4:00 pm and concluding at 4:20 pm. This virtual format allowed shareholders to transact business remotely in compliance with regulatory norms.
Key resolutions passed
Shareholders approved three ordinary resolutions during the session:
- Adoption of the audited financial statements for FY26, along with the reports of the Directors and Auditors.
- Reappointment of Kelash Bunkar (DIN: 10911360) as a director retiring by rotation.
- Appointment of M/s. Goenka Mehta & Associates Chartered Accountants, Rajkot (Firm Registration No: 129445W), as statutory auditors and fixation of their remuneration.
All businesses were transacted and passed by the shareholders present at the meeting. Details regarding the voting results, as required under Regulation 44(3) of the Listing Regulations, are being submitted separately to the stock exchange.
Historical Stock Returns for Biogen Pharmachem
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.57% | 0.0% | -3.57% | -40.00% | -63.51% | -49.06% |
How might the appointment of Goenka Mehta & Associates influence Biogen Pharmachem's financial reporting standards and audit rigor in the upcoming fiscal year?
What specific strategic priorities will Kelash Bunkar focus on during his renewed directorship to drive the company's growth trajectory?
Will the adoption of the FY26 audited statements reveal any significant shifts in revenue composition or margin trends compared to previous years?


































